TONIX MEDS
PharmaTONIX MEDS is a pharmaceutical company focused on Neurology. Key products include ZEMBRACE SYMTOUCH.
TONIX MEDS at a Glance
- Fast trial execution (11 months median completion)
TONIX MEDS's Key Drugs
TONIX MEDS's core commercial portfolio centers on ZEMBRACE SYMTOUCH, TOSYMRA, spanning Neurology — its most strategically important drugs approved in the last 15 years.
TONIX MEDS's Recent FDA Approvals
New NDA/BLA approvals for TONIX MEDS over the last two years — novel drugs only, excluding generics and label supplements.
TONIX MEDS's Therapeutic Areas
TONIX MEDS's approved drugs and pipeline span 1 therapeutic area, led by Neurology, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
TONIX MEDS's Top Competitors
TONIX MEDS's closest competitors by therapeutic-area and drug-target overlap include Pfizer, AbbVie, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
TONIX MEDS Pipeline Snapshot
Active clinical trials for TONIX MEDS across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • ZEMBRACE SYMTOUCH leads revenue
- • 2 key drugs tracked
Trial Catalysts
- • Neurology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 7/11 completed
- • Speed: 11 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (2)
Discontinued (0)
Company Info
- First Approval
- 2016-01-28
- Latest
- 2019-06-10
- Applications
- 2
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges